Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.

NCT Number	NCT07073365
Lead Sponsor	Pusan National University Hospital
Conditions	Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor
Enrollment	70 participants
Start Date	2025-07-01
Primary Completion	2030-06-30 (estimated)
Study Completion	2031-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-30